Advances in cancer immunotherapy: The role of super NK and super CAR-T cells

Immunotherapy has over the recent past established itself as one of the more promising strategies in the treatment of several cancers. Among the described ones, the most efficient are natural killer (NK) cells and chimeric antigen receptor T (CAR-T) cells and both of them are known to be rather effective in killing the cancer cells. Such interventions recently attempted to develop these immune cells have enhanced its beneficence and includes super NK and super CAR-T cells. Cell therapies both types employ the body immunity in order to achieve a superior Tumour killing mechanism over conventional approaches. In this sense, super NK cells provide an out-of-shelf, allogeneic solution that would minimize the early immunological adverse reactions, compared to super CAR-T cells where the outcome is more personalized, with impressive responses in hematological cancer diseases. Nevertheless, certain critical complications, including cytokine release syndrome and neurotoxicity have been noted which require more study and innovation. This review aims at considering the possibilities of these therapies, more precisely, speaking about the roles of such therapies, their functions, types and concerning the development of cancer immunotherapy.